Brokerages expect that Prestige Consumer Healthcare Inc (NYSE:PBH) will report sales of $232.23 million for the current quarter, according to Zacks. Four analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $230.80 million and the highest estimate coming in at $234.70 million. Prestige Consumer Healthcare posted sales of $253.98 million in the same quarter last year, which suggests a negative year-over-year growth rate of 8.6%. The business is expected to report its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full-year sales of $954.88 million for the current year, with estimates ranging from $954.00 million to $955.90 million. For the next financial year, analysts forecast that the business will post sales of $964.10 million, with estimates ranging from $963.50 million to $964.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.72 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.02. The company had revenue of $241.03 million for the quarter, compared to analyst estimates of $237.22 million. Prestige Consumer Healthcare had a negative net margin of 3.67% and a positive return on equity of 12.45%. The company’s revenue was down 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 earnings per share.
A number of equities analysts recently commented on PBH shares. Royal Bank of Canada reaffirmed a “buy” rating and set a $97.00 price target on shares of Prestige Consumer Healthcare in a research report on Friday, March 15th. TheStreet lowered shares of Prestige Consumer Healthcare from a “c” rating to a “d+” rating in a research report on Friday, May 10th. Zacks Investment Research raised shares of Prestige Consumer Healthcare from a “sell” rating to a “hold” rating and set a $31.00 price target on the stock in a research report on Tuesday, May 28th. CIBC reaffirmed a “hold” rating and set a $84.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, May 27th. Finally, ValuEngine raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a research report on Monday, April 29th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $57.77.
Large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted…